Exercice des derniers bons de souscriptions et émission d’actions

Paris, France et Camberley, Royaume-Uni – 19 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), un spécialiste international du diagnostic clinique, annonce qu’il a émis un total de 6 370 728 nouvelles actions ordinaires de €1/15 chacune dans le capital de la société (“Actions Ordinaires”) suite à l’exercice de bons de souscription

Visit Page

Final Warrant Exercise and Issue of Equity

Paris, France and Camberley, UK – 19 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has issued a total of 6,370,728 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary Shares”) pursuant to the exercise of warrants as detailed below. http://novacyt.com/wp-content/uploads/2020/02/Novacyt-final-Exercise-of-Warrants-and-issue-of-equity-ENGLISH-19.02.2020.pdf

Visit Page

Exercice de bons de souscription et émission d’actions

Paris, France et Camberley, Royaume-Uni – 19 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce qu’elle a reçu de YA II CD, Ltd un avis d’exercice de bons de souscription de 300 000 de nouvelles actions ordinaires de 1€/15 chacune dans le capital de la société

Visit Page

Exercise of Warrants and Issue of Equity

Paris, France and Camberley, UK – 19 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has received notice from YA II CD, Ltd of an exercise of warrants to subscribe for 300,000 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary

Visit Page

Exercise of Warrants and Issue of Equity

Paris, France and Camberley, UK – 18 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has received notice from YA II CD, Ltd of an exercise of warrants to subscribe for 228,541 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary

Visit Page

Exercice de bons de souscription et émission d’actions

Paris, France et Camberley, Royaume-Uni – 18 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce qu’elle a reçu de YA II CD, Ltd un avis d’exercice de bons de souscription de 228 541 nouvelles actions ordinaires de 1€/15 chacune dans le capital de la société (“Actions

Visit Page

Lancement du nouveau test CE-IVD du coronavirus

Paris, France et Camberley, Royaume-Uni – 17 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer que sa division de diagnostic moléculaire, Primerdesign, a lancé son test moléculaire CE-Mark pour la détection clinique du nouveau coronavirus (COVID-19). http://novacyt.com/wp-content/uploads/2020/02/Novacyt-CE-mark-approval-coronavirus-test-FR.pdf

Visit Page

Launch of CE-IVD Marked novel coronavirus test

Paris, France and Camberley, UK – 17 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that its molecular diagnostics division, Primerdesign, has launched its CE-Mark molecular test for the clinical detection of the novel coronavirus (COVID-19). http://novacyt.com/wp-content/uploads/2020/02/Novacyt-CE-mark-approval-coronavirus-test-ENG.pdf

Visit Page

Mise à jour sur le test du coronavirus approuvé par le marquage CE

Paris, France et Camberley, Royaume-Uni – 14 février 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer que, suite à son annonce du 7 février 2020, sa filiale, Primerdesign Limited, est en mesure de lancer un test du nCoV approuvé par le marquage CE dans

Visit Page

Update on CE Mark Approved coronavirus test

Paris, France and Camberley, UK – 14 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that, further to its announcement on 7 February 2020, its subsidiary, Primerdesign Limited, is on schedule to launch a CE-Mark approved nCoV test in the week commencing 17 February

Visit Page